Why Supernus Pharmaceuticals (SUPN) Is Getting Attention Today
Supernus Pharmaceuticals (SUPN) has drawn attention after recent share performance data showed mixed signals, with the stock edging up about 0.5% over the past day but declining roughly 11% in the past 3 months.
Set against a 1-year total shareholder return that is down 10.31%, the recent 90-day share price return decline of 11.69% suggests that momentum for Supernus Pharmaceuticals has been fading rather than building, even with a 3-year total shareholder return of 59.09% still in the background.
Compare Supernus Pharmaceuticals with a curated group of CNS and healthcare peers by scanning the 34 healthcare AI stocks that could be next in line for sharp sentiment shifts.
Supernus Pharmaceuticals has a broad CNS portfolio and a pipeline in motion, yet the share price has slipped in recent months. Are you being paid enough today for the risk in this story, or not?
Most Popular Narrative: 30.3% Undervalued
On the most followed narrative, Supernus Pharmaceuticals screens materially cheaper than its $61.75 fair value estimate, with the last close at $43.05. The real question is whether that gap lines up with the business that analysts describe.
Significant balance sheet resources and a focus on transactions remain in play, now exemplified by the proposed all stock merger of equals with Indivior that would combine approximately $2.2b of pro forma net revenue, $888m of pro forma adjusted EBITDA and expected annual cost synergies of $125m. This can lift overall earnings power and margins for the combined CNS portfolio.
See why 8 investors see Supernus Pharmaceuticals as 30% undervalued.
Result: Fair Value of $61.75 (UNDERVALUED)
Still, the Supernus Pharmaceuticals story can shift quickly if the Indivior merger stumbles or if sales growth remains close to the firm’s slower five-year average.
Find out about the key risks to this Supernus Pharmaceuticals narrative.
Next Steps
Sentiment around Supernus Pharmaceuticals is clearly split, which is exactly why fresh eyes on the numbers can help you move faster than the crowd. To see what optimism is already baked into the thesis, start by reviewing the 3 key rewards.
Looking for more Supernus Pharmaceuticals sized opportunities?
If you stop at Supernus Pharmaceuticals, you miss the broader field of ideas. Use the Simply Wall Street Screener to quickly surface differentiated setups before everyone else notices.
- Target value first by checking companies that combine quality fundamentals with appealing valuations through the 29 high quality undervalued stocks.
- Prioritise resilience by reviewing the list of solid balance sheet and fundamentals (25 results) and focus on businesses with stronger financial footing.
- Hunt for fresh angles by scanning the 20 high quality undiscovered gems and spot stories that are not yet crowded.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com